ProKidney Financials - Benzinga

ProKidney Corp

PROKNASDAQ

Trade with Public

Trade with Public

$1.60

-0.08-4.76%

In chiusura: Sep 24, 5:00 PM EST

$1.62

-0.06-3.57%

Pre-mercato: 6:02 AM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

ProKidney Financials

ProKidney (PROK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the

Benzinga Newsdesk

PRO
ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 7.69 percent decrease over losses of $(0.13) per share from the same period last year. The

Benzinga Newsdesk

PRO
ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 23.89 percent. This is a 12.5 percent increase over losses of $(0.16) per share from the

Benzinga Newsdesk

PRO
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14) per share from the

Benzinga Newsdesk

PRO
ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the

Benzinga Newsdesk

PRO
ProKidney Q1 EPS $(0.13) Beats $(0.16) Estimate, Sales $230.00K

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved